Short Interest in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Decreases By 39.7%

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) saw a significant decline in short interest in February. As of February 15th, there was short interest totalling 4,100 shares, a decline of 39.7% from the January 31st total of 6,800 shares. Currently, 0.3% of the shares of the company are short sold. Based on an average daily volume of 33,300 shares, the short-interest ratio is presently 0.1 days.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on Galmed Pharmaceuticals in a research note on Monday, February 24th. They issued a “sell” rating on the stock.

Institutional Investors Weigh In On Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned about 3.97% of Galmed Pharmaceuticals as of its most recent SEC filing. 76.14% of the stock is owned by institutional investors and hedge funds.

Galmed Pharmaceuticals Trading Up 0.6 %

NASDAQ GLMD traded up $0.01 on Friday, reaching $2.17. 10,661 shares of the stock were exchanged, compared to its average volume of 695,896. The firm has a market capitalization of $1.40 million, a PE ratio of -0.13 and a beta of 0.66. Galmed Pharmaceuticals has a one year low of $2.11 and a one year high of $23.80. The company’s 50-day simple moving average is $2.80 and its two-hundred day simple moving average is $3.58.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.